Bio-Gene Technology Ltd (BGT) - Cash Flow Conversion Efficiency

Latest as of December 2025: -0.811x

Based on the latest financial reports, Bio-Gene Technology Ltd (BGT) has a cash flow conversion efficiency ratio of -0.811x as of December 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-946.61K ≈ $-669.78K USD) by net assets (AU$1.17 Million ≈ $825.57K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Bio-Gene Technology Ltd - Cash Flow Conversion Efficiency Trend (2014–2025)

This chart illustrates how Bio-Gene Technology Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read BGT current and long-term liabilities for a breakdown of total debt and financial obligations.

Bio-Gene Technology Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Bio-Gene Technology Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
BIG Industries Bhd
KLSE:7005
-0.091x
Conduit Holdings Ltd
LSE:CRE
0.106x
Turnstone Biologics Corp. Common Stock
NASDAQ:TSBX
-0.292x
Avalon Holdings Corporation
NYSE MKT:AWX
0.039x
Eddy Smart Home Solutions Ltd
V:EDY
0.095x
Star Minerals Ltd
AU:SMS
-0.110x
Conquest Resources Ltd
V:CQR
-0.100x
Tempo Inti Media Tbk
JK:TMPO
-0.034x

Annual Cash Flow Conversion Efficiency for Bio-Gene Technology Ltd (2014–2025)

The table below shows the annual cash flow conversion efficiency of Bio-Gene Technology Ltd from 2014 to 2025. For the full company profile with market capitalisation and key ratios, see Bio-Gene Technology Ltd (BGT) market capitalisation.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$1.63 Million
≈ $1.15 Million
AU$-2.54 Million
≈ $-1.80 Million
-1.563x -58.38%
2024-06-30 AU$2.79 Million
≈ $1.97 Million
AU$-2.75 Million
≈ $-1.95 Million
-0.987x +2.98%
2023-06-30 AU$3.22 Million
≈ $2.28 Million
AU$-3.28 Million
≈ $-2.32 Million
-1.017x -14751.29%
2022-06-30 AU$6.27 Million
≈ $4.44 Million
AU$43.52K
≈ $30.79K
0.007x +101.61%
2021-06-30 AU$4.25 Million
≈ $3.00 Million
AU$-1.83 Million
≈ $-1.29 Million
-0.430x -56.90%
2020-06-30 AU$6.00 Million
≈ $4.25 Million
AU$-1.64 Million
≈ $-1.16 Million
-0.274x +38.40%
2019-06-30 AU$4.95 Million
≈ $3.50 Million
AU$-2.20 Million
≈ $-1.56 Million
-0.445x -29.44%
2018-06-30 AU$6.91 Million
≈ $4.89 Million
AU$-2.37 Million
≈ $-1.68 Million
-0.344x -327.50%
2017-06-30 AU$9.07 Million
≈ $6.42 Million
AU$-729.15K
≈ $-515.92K
-0.080x +90.93%
2016-06-30 AU$473.35K
≈ $334.92K
AU$-419.35K
≈ $-296.71K
-0.886x -440.17%
2014-06-30 AU$290.03K
≈ $205.21K
AU$-47.57K
≈ $-33.66K
-0.164x --

About Bio-Gene Technology Ltd

AU:BGT Australia Biotechnology
Market Cap
$8.20 Million
AU$11.59 Million AUD
Market Cap Rank
#27329 Global
#1398 in Australia
Share Price
AU$0.04
Change (1 day)
+2.70%
52-Week Range
AU$0.02 - AU$0.04
All Time High
AU$0.34
About

Bio-Gene Technology Limited, an agtech development company, engages in the development and commercialization of naturally derived insecticide products in Australia and internationally. Its products include Flavocide, a synthetically produced nature-identical compound; and Qcide, a natural plant-derived oil with high levels of tasmanone. The company has a research collaboration agreement with Jame… Read more